Last updated on December 2019

A Study of Intravenous Perampanel in Japanese Participants With Epilepsy

Brief description of study

The purpose of the study is to evaluate the safety and tolerability of perampanel administered as a 30-minute intravenous infusion after switching from oral tablets (8 to 12 milligrams per day [mg/day]) as an adjunctive therapy in participants with epilepsy with partial onset seizures (including secondarily generalized seizures) or primary generalized tonic-clonic seizures.

Clinical Study Identifier: NCT03754582

Find a site near you

Start Over

Eisai trial site 12

Sapporo, Japan
  Connect »